Meridian Investment Counsel Boosts Gilead Sciences Holdings

The investment firm increased its stake in the biopharmaceutical company by over 50% in the fourth quarter.

Apr. 5, 2026 at 10:37am

Got story updates? Submit your updates here. ›

Meridian Investment Counsel Inc. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 51.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 32,120 shares of the biopharmaceutical company's stock after buying an additional 10,953 shares during the period.

Why it matters

This investment increase by Meridian Investment Counsel suggests growing confidence in Gilead Sciences' outlook and performance. As a major institutional investor, Meridian's portfolio moves can provide insights into broader market trends and investor sentiment around the biopharmaceutical sector.

The details

Gilead Sciences comprises about 0.9% of Meridian Investment Counsel's holdings, making the stock its 27th largest position. The investment firm's holdings in Gilead Sciences were worth $3,942,000 at the end of the most recent quarter.

  • Meridian Investment Counsel increased its Gilead Sciences holdings during the fourth quarter of 2025.

The players

Meridian Investment Counsel Inc.

An institutional investment firm that manages a portfolio of stocks, including a position in Gilead Sciences.

Gilead Sciences, Inc.

A biopharmaceutical company focused on developing antiviral therapies, oncology treatments, and other innovative medicines.

Got photos? Submit your photos here. ›

The takeaway

Meridian Investment Counsel's increased stake in Gilead Sciences suggests the firm sees strong potential in the biopharmaceutical company's future performance and growth prospects. This move could signal broader investor optimism around Gilead's pipeline and market positioning.